These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37542281)

  • 1. Treatment regimens, patient reported outcomes and health-related quality of life in children with moderate and severe hemophilia A in China: using real-world data.
    Zhang L; Zhang P; Chen W
    Orphanet J Rare Dis; 2023 Aug; 18(1):232. PubMed ID: 37542281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective study of health-related quality of life of boys with severe haemophilia A in China: comparing on-demand to prophylaxis treatment.
    Wu R; Sun J; Xiao J; Liu Y; Xue F; Wang H; Tang L; Zhao Y; Li K; Yang R; Hu Y; Luke KH; Poon MC; Blanchette VS; Usuba K; Young NL
    Haemophilia; 2017 May; 23(3):430-436. PubMed ID: 28345299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Long-term health-related quality of life and related factors in children with severe hemophilia A who received regular low-dose prophylaxiss].
    Li Z; Zhou Y; Zhang SN; Li KX; Zhao YQ; Wang SJ; Xiao J
    Zhonghua Yi Xue Za Zhi; 2024 Jul; 104(29):2745-2750. PubMed ID: 39075994
    [No Abstract]   [Full Text] [Related]  

  • 4. Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B.
    Olasupo OO; Lowe MS; Krishan A; Collins P; Iorio A; Matino D
    Cochrane Database Syst Rev; 2021 Aug; 8(8):CD014201. PubMed ID: 34407214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efficacy and safety of prophylaxis with recombinant factor VIII in Chinese pediatric patients with hemophilia A: a multi-center, retrospective, non-interventional, phase IV (ReCARE) study.
    Li C; Zhang X; Zhao Y; Wu R; Hu Q; Xu W; Sun J; Yang R; Li X; Zhou R; Lian S; Gu J; Wu J; Hou Q
    Curr Med Res Opin; 2017 Jul; 33(7):1223-1230. PubMed ID: 28326849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of standard prophylaxis versus on-demand treatment with bayer's sucrose-formulated recombinant FVIII (rFVIII-FS) in Chinese children with severe hemophilia A.
    Zhao Y; Xiao J; Yang R; Wu R; Hu Y; Beckmann H; Wu J; Hou Q; Sun J
    Pediatr Hematol Oncol; 2017 Apr; 34(3):138-148. PubMed ID: 28727494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of late prophylaxis in hemophilia on joint status: a randomized trial.
    Manco-Johnson MJ; Lundin B; Funk S; Peterfy C; Raunig D; Werk M; Kempton CL; Reding MT; Goranov S; Gercheva L; Rusen L; Uscatescu V; Pierdominici M; Engelen S; Pocoski J; Walker D; Hong W
    J Thromb Haemost; 2017 Nov; 15(11):2115-2124. PubMed ID: 28836341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining the impact of hemophilia: the Academic Achievement in Children with Hemophilia Study.
    Shapiro AD; Donfield SM; Lynn HS; Cool VA; Stehbens JA; Hunsberger SL; Tonetta S; Gomperts ED;
    Pediatrics; 2001 Dec; 108(6):E105. PubMed ID: 11731632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term joint outcomes of regular low-dose prophylaxis in Chinese children with severe haemophilia A.
    Wu Y; Lu J; Zhou Y; Li K; Liu Y; Liu S; Li Z; Zhao Y; Poon MC; Xiao J
    Haemophilia; 2021 Mar; 27(2):237-244. PubMed ID: 33550696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII.
    Reding MT; Ng HJ; Poulsen LH; Eyster ME; Pabinger I; Shin HJ; Walsch R; Lederman M; Wang M; Hardtke M; Michaels LA
    J Thromb Haemost; 2017 Mar; 15(3):411-419. PubMed ID: 27992112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health-related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors-A non-interventional study.
    Oldenburg J; Tran H; Peyvandi F; Núñez R; Trask P; Chebon S; Mahlangu JN; Lehle M; Jiménez-Yuste V; von Mackensen S
    Haemophilia; 2021 May; 27(3):398-407. PubMed ID: 33576546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors.
    Chai-Adisaksopha C; Nevitt SJ; Simpson ML; Janbain M; Konkle BA
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011441. PubMed ID: 28944952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term low-dose secondary prophylaxis for severe/moderate haemophilia A children is beneficial to reduce bleed and improve daily activity, but there are obstacle in its execution: a multi-centre pilot study in China.
    Tang L; Wu R; Sun J; Zhang X; Feng X; Zhang X; Luke KH; Poon MC
    Haemophilia; 2013 Jan; 19(1):27-34. PubMed ID: 23231016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment-related outcome from patient report outcome (PRO) of children with severe and moderate hemophilia A in China: An analysis report of registration data from patient organization "hemophilia home care center".
    Guan T; Ai D; Zhao N; Liu G; Yao W; Chen Z; Li Z; Zhou Y; Wu R
    Haemophilia; 2023 Nov; 29(6):1467-1474. PubMed ID: 37718575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylaxis use of clotting factor replacement products in people with non-severe haemophilia: A review of the literature.
    Iorio A; Königs C; Reding MT; Rotellini D; Skinner MW; Mancuso ME; Berntorp E
    Haemophilia; 2023 Jan; 29(1):33-44. PubMed ID: 36224704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden.
    Henry N; Jovanović J; Schlueter M; Kritikou P; Wilson K; Myrén KJ
    J Med Econ; 2018 Apr; 21(4):318-325. PubMed ID: 29139314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes of low-dose pharmacokinetic-guided extended half-life versus low-dose standard half-life factor VIII concentrate prophylaxis in haemophilia A patients.
    Rakmanotham A; Moonla C; Sosothikul D
    Haemophilia; 2023 Jan; 29(1):156-164. PubMed ID: 36409282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PK-driven prophylaxis versus standard prophylaxis: When a tailored treatment may be a real and achievable cost-saving approach in children with severe hemophilia A.
    Pasca S; Milan M; Sarolo L; Zanon E
    Thromb Res; 2017 Sep; 157():58-63. PubMed ID: 28692842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A.
    Chowdary P; Mullins ES; Konkle BA; McGuinn C; Park YS; Stasyshyn O; Zulfikar B; Engl W; Tangada S
    Haemophilia; 2020 Jul; 26(4):e168-e178. PubMed ID: 32597029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.
    Stobart K; Iorio A; Wu JK
    Cochrane Database Syst Rev; 2006 Apr; (2):CD003429. PubMed ID: 16625581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.